The Limited Times

Now you can see non-English news...

"Remdesivir works" - Coronavirus drugs may be available soon

2020-05-10T17:06:10.687Z


A drug against the coronavirus is urgently needed. Now the head of the German study has spoken out: "Remdesivir works" and could be available soon.


A drug against the coronavirus is urgently needed. Now the head of the German study has spoken out: "Remdesivir works" and could be available soon.

  • A drug that helps covid-19 * is urgently needed in the corona pandemic *
  • Many hopes rest on the antiviral agent Remdesivir , which was developed against Ebola
  • Initial results from the USA were promising, and the drug could soon be used

Update of May 10, 2020: After a few weeks ago promising results for the active ingredient remdesivir as a remedy for the coronavirus were known in the USA , there are now positive signals from Germany: The preparation remdesivir  “we will be available within weeks or a few months have, ”says Gerd Fätkenheuer, head of infectiology at Cologne University Hospital, the Cologne City Gazette.

In Remdesivir is a drug that was developed against Ebola. It is currently being researched in Germany in a study because medication is urgently needed in the corona crisis . The study is in a "very advanced stage", says Fätkenheuer. "We can say: Remdesivir works". It has already been shown that remdesivir alleviates and shortens the severe course of a Covid 19 disease .

Remdesivir as a drug against corona: side effects not known

Significant side effects of remdesivir are not known, but need to be investigated further. The drug lies, according to calculations of a British researcher at a cost of approximately ten euro for a ten-day treatment. "How expensive it will then be to sell is another question," says Fätkenheuer.

Compared to the Kölner Stadt-Anzeiger, the researcher warns that the virus "spreads slowly, as it were under the radar, and that there is a second wave that is repeatedly mentioned, which will then be of incomparably greater force".

Remdesivir against the coronavirus: drug urgently needed

First message from April 17, 2020: The antiviral active ingredient remdesivir was originally developed against Ebola , but it is now one of the active ingredients with the highest hopes that they may help against the Sars-CoV-2 coronavirus . In a hospital in Chicago, US researchers are conducting a clinical study with the drug - apparently with promising results: As the health portal "Stat" reports, several corona patients in the hospital reacted positively to remdesivir .

Doctors at the hospital would see "rapid recovery from fever and respiratory symptoms" in corona patients treated with remdesivir, "almost all patients" would be discharged from the clinic in less than a week, the report said. Accordingly, 125 people with Covid-19 were included  in the clinical trial. 113 of these patients were "seriously ill", all 125 patients received Remdesivir infusions daily  .

Does Remdesivir help against Covid-19? Promising results from the USA

There are also studies at other clinics in the USA, from which no results have yet been published. Gilead Sciences , the manufacturer of remdesivir , said in a statement: "What we can say at this stage is that we are waiting for data from the other studies." Previously, the data was expected for April. "Stat" assumes that the clinical trial data could be published "at any time".

"Most of our patients are seriously ill and most of them leave the hospital after six days," quotes the "Stat" portal Kathleen Mullane from the University of Chicago. Mullane said this in a video conference with other members of her faculty, a recording of which is on the portal and was later confirmed by Mullane. However, "drawing any conclusions" from the data is "premature and scientifically unreliable", the University of Chicago said in a statement on the recording.

Active ingredient against corona: Look at the remdesivir study carefully

In fact, the data on Remdesivir has to be viewed  with caution for the time being: it has not yet been independently verified, and further studies are ongoing. Mullane further commented in the video recording that there was no placebo group to control in the remdesivir study .

The active ingredient remdesivir integrates into the RNA and inhibits the proliferation of the coronavirus Sars-CoV-2 . Remdesivir is administered intravenously by infusion and is considered a broad-spectrum antiviral that could be effective against various viruses - in addition to Sars-CoV-2, also against the related pathogens of Sars and Mers or the Ebola virus.

Coronavirus drug: Remdesivir not yet approved in Germany

Approved is Remdesivir not in Germany so far. In Germany, the active ingredient is currently available directly from the manufacturer in individual cases after prior testing *. These are so-called "individual healing attempts". Since the beginning of April, Remdesivir has been on the list of confirmed drug hardship programs by the Federal Institute for Drugs and Medical Devices (BfArM). WHO prioritized research into remdesivir in clinical trials back in January.

The President of the BfArM, Karl Broich, expects the first trial results on the treatment of Covid-19 in three months. Until then, data from two large studies with remdesivir in Germany are expected, Broich said. Overall, there are some promising therapeutic approaches.

Drug against Covid-19 is eagerly awaited

The coming months should show whether remdesivir is the much-awaited drug that will help against Covid-19 until a vaccine against Sars-CoV-2 * has been developed. An effective agent that alleviates Covid-19 disease could support efforts to prevent health systems from collapsing until a vaccine is developed.

By Tanja Banner

Studies give hope: Remdesivir drug works in Covid 19 patients.

* fr.de is part of the nationwide Ippen-Digital central editorial office.

Source: merkur

All life articles on 2020-05-10

You may like

Trends 24h

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.